MedTrace Logo

Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

NCT01297400 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-03-16

No results posted yet for this study

Summary

To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.

Conditions

  • Burns

Interventions

DRUG

Investigational Drug, MW-III

Topical application, twice a day

DRUG

Silvadene® Cream 1% [Silver Sulfadiazine]

Topical application, twice a day

Sponsors & Collaborators

  • Skingenix, Inc.

    lead INDUSTRY

Principal Investigators

  • Kevin Foster · Valleywise Health Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-11
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States
  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01297400 on ClinicalTrials.gov